Trial Profile
Real-world experience of generalized lipodystrophy patients enrolled in the metreliptin early access program
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 15 Nov 2018
Price :
$35
*
At a glance
- Drugs Metreleptin (Primary)
- Indications Lipodystrophy
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 15 Nov 2018 New trial record
- 14 Nov 2018 Results(n=28) of the early access program,presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research